Search

Author/Creator Matthews, Jessica E

1. Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Issue 9 (September 2019)

Authors:
Aboud, Michael; Orkin, Chloe; Podzamczer, Daniel; Bogner, Johannes R; Baker, David; Khuong-Josses, Marie-Aude; Parks, David; Angelis, Konstantinos; Kahl, Lesley P; Blair, Elizabeth A; Adkison, Kimberly; Underwood, Mark; Matthews, Jessica E; Wynne, Brian; Vandermeulen, Kati; Gartland, Martin; Smit...
Journal:
Lancet
Issue:
Volume 6:Issue 9(2019)
Page Start:
e576
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks. (1st March 2023)

Authors:
Rolle, Charlotte-Paige; Berhe, Mezgebe; Singh, Tulika; Ortiz, Roberto; Wurapa, Anson; Ramgopal, Moti; Jayaweera, Dushyantha T; Leone, Peter A; Matthews, Jessica E; Cupo, Michael; Underwood, Mark R; Angelis, Konstantinos; Wynne, Brian R; Merrill, Deanna; Nguyen, Christopher; van Wyk, Jean; Zolopa,...
Journal:
Open forum infectious diseases
Issue:
Volume 10:Number 3(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search